Şirket hakkında

Concarlo Holdings focuses on developing solutions for drug-resistant breast cancer. Its technologies, including IpY, a cdk inhibitor, as well as ApY, an antibody focus on increasing drug efficacy and diagnostic evaluations for ER/PR+ Her 2- patients.

US
Bilinmeyen
Doğrulanmamış şirket